ReviewCurrent hematologic malignancy reports2016
Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You.
Review in Current hematologic malignancy reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 68 citations in OpenAlex.
- CD4/CD8-p56Biomolecules · 2025Review
- Present and future of cancer nano-immunotherapy: opportunities, obstacles and challenges.Molecular cancer · 2025Review
- CAR-NK Cells Generated with mRNA-LNPs Kill Tumor Target Cells In Vitro and In Vivo.International journal of molecular sciences · 2023Article
- Anti-ROR1 CAR-T cells: Architecture and performance.Frontiers in medicine · 2023Review
- Editorial: T-Cell Signaling Networks in Health and Disease.Frontiers in immunology · 2022Article
- CAR-T Engager proteins optimize anti-CD19 CAR-T cell therapies for lymphoma.Oncoimmunology · 2022Article
- Novel CD37, Humanized CD37 and Bi-Specific Humanized CD37-CD19 CAR-T Cells Specifically Target Lymphoma.Cancers · 2021Article
- Adoptive cell therapy: Living drugs against cancer.The Journal of experimental medicine · 2020Article
- The global chimeric antigen receptor T (CAR-T) cell therapy patent landscape.Nature biotechnology · 2020Article
- Lingering effects of chemotherapy on mature T cells impair proliferation.Blood advances · 2020Article
- A narrative review of critical factors for better efficacy of CD19 chimeric antigen receptor T cell therapy in the treatment of B cell malignancies.Translational cancer research · 2020Review
- CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overview.Bone marrow transplantation · 2020Review
- B-Cell Maturation Antigen (BCMA) as a Target for New Drug Development in Relapsed and/or Refractory Multiple Myeloma.International journal of molecular sciences · 2020Review
- Global Perspective on the Development of Genetically Modified Immune Cells for Cancer Therapy.Frontiers in immunology · 2020Review
- Manufacturing and Management of CAR T-Cell Therapy in "COVID-19's Time": Central Versus Point of Care Proposals.Frontiers in immunology · 2020Review
- Article
- Modulation of immune checkpoint molecule expression in mantle cell lymphoma.Leukemia & lymphoma · 2019Article
- Emerging Cellular Therapies for Cancer.Annual review of immunology · 2019Review
- Naïve T-cell Deficits at Diagnosis and after Chemotherapy Impair Cell Therapy Potential in Pediatric Cancers.Cancer discovery · 2019Article
- From Biology to Therapy: The CLL Success Story.HemaSphere · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genetic redirection of T lymphocytes allows us to unleash these potent cellular immune effectors against cancer. Chimeric antigen receptor (CAR) T cells are the best-in-class example that genetic engineering of T cells can lead to deep and durable responses, as has been shown in several clinical trials for CD19+ B cell malignancies. As a consequence, in the last few years, several academic institutions and commercial partners have started developing anti-CD19 CAR T cell products. Although most of these T cell products are highly effective in vivo, basic differences among them can generate different performance characteristics and thereby impact their long-term clinical outcome. Several strategies are being implemented in order to solve the current open issues of CART19 therapy: (i) increasing efficacy against indolent B cell leukemias and lymphomas, (ii) avoiding or preventing antigen-loss relapses, (iii) reducing and managing toxicity, and (iv) bringing this CART therapy to routine clinical practice. The field of CART therapies is thriving, and exciting new avenues are opening for both scientists and patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.